1883 0.26x10-3 versus 4.07±0.33x10-3, p<0.01) were significantly lower than those of normal control mice, and there was no significant difference in body weight (18.0±1.6 g versus 18.2±2.7 g, p=NS) between treated mice and normal controls. Thus, the effect of captopril in the later stage of coxsackievirus B3 myocarditis reported by Rezkalla et al may merely reflect the drug effect itself without an effect on myocarditis. We believe that more work should be done before it can be concluded that captopril has a beneficial effect in the later stage of acute myocarditis. late phase; however, the study was not designed to address the mechanism(s) that might be involved. A reduction in left ventricular mass in a case of cardiomyopathy may be beneficial. Note that this reduction in this particular model was associated with a lesser degree of liver congestion in the late (day 30) study group. Of interest is that the reduction in heart weight in normal treated mice in the study conducted by Matsumori et al was a modest 12%, whereas in our study the reduction on days 6, 20, and 30 were 46%, 43%, and 36%, respectively. It is conceivable that the reduction observed in our study is a combination of a nonspecific effect of captopril on the heart plus a specific effect on hearts infected with coxsackievirus. We agree with Matsumori et al that this will need further studies and we did conclude in our manuscript that "further testing will be needed before a randomized human study can be considered. The discussion portion of this paper lumps together myocardial stunning and hibernation. Scientifically, there may be no basis for such grouping, because "myocardial hibernation" is still a term in search of a reality. Rahimtoola,4 who coined the word "hibernation," has recently suggested that 1) the mechanism for hibernation is not known; 2) it is not known why severely ischemic hearts hibernate; 3) the modality that should be used to detect hibernation is not established; 4) it is not known how long the myocardium can hibernate, and 5) it is not known how soon after reperfusion is instituted the hibernating myocardium normalizes function.
Reply
We appreciate the comments made by Matsumori et al on our article reporting the effect of captopril in acute murine viral myocarditis.1 While they agree that the beneficial effects are clear in the early treatment group, they express doubt concerning its beneficial effects in the late phase because it may be nonspecific. In fact, administration of captopril has been previously shown to decrease left ventricular mass in normal Sprague-Dawley rats2 and in patients with essential hypertension.3 In our study we reported a decrease in left ventricular mass when captopril was administered in the late phase; however, the study was not designed to address the mechanism(s) that might be involved. A reduction in left ventricular mass in a case of cardiomyopathy may be beneficial. Note that this reduction in this particular model was associated with a lesser degree of liver congestion in the late (day 30) study group. Of interest is that the reduction in heart weight in normal treated mice in the study conducted by Matsumori et al was a modest 12%, whereas in our study the reduction on days 6, 20, and 30 were 46%, 43%, and 36%, respectively. It is conceivable that the reduction observed in our study is a combination of a nonspecific effect of captopril on the heart plus a specific effect on hearts infected with coxsackievirus. We agree with Matsumori et al that this will need further studies and we did conclude in our manuscript that "further testing will be needed before a randomized human study can be considered." S. Rezkalla The discussion portion of this paper lumps together myocardial stunning and hibernation. Scientifically, there may be no basis for such grouping, because "myocardial hibernation" is still a term in search of a reality. Rahimtoola,4 who coined the word "hibernation," has recently suggested that 1) the mechanism for hibernation is not known; 2) it is not known why severely ischemic hearts hibernate; 3) the modality that should be used to detect hibernation is not established; 4) it is not known how long the myocardium can hibernate, and 5) it is not known how soon after reperfusion is instituted the hibernating myocardium normalizes function.
At the present time, there is no experimental model to demonstrate the existence of hibernation. The experimental design of Matsuzaki et al5 of 5 hours of partial ischemia can hardly be considered a model for hibernating myocardium in the context used by Rahimtoola.4 In sum, many readers will probably wonder whether van 
